Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others People taking popular new ...

People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and ...

The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...

Groundbreaking GLP-1 drugs like Ozempic, Mounjaro and Wegovy are revolutionising weight loss, with studies showing ...

Ozempic, Mounjaro and Wegovy are now cultural symbols of weight loss. These medications help control blood sugar and aid ...

This article was reviewed by Darragh O’Carroll, MD. Long-Term Side Effects of Wegovy® Key takeaways: The long-term side ...

HONG KONG, Nov. 3, 2025 /PRNewswire/ -- Leading global healthcare company Novo Nordisk announces the launch of Wegovy® in Hong Kong, now available at private clinics and selected pharmacies.

New survey data shows 37 percent of US adults are currently classed as obese, down from a record high of 39.9 percent in 2022 ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...